# Piqray (alpelisib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/alpelisib

> The FDA approved Piqray (alpelisib), sponsored by NOVARTIS AG (NVS), on April 24, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Piqray (alpelisib) |
| Codes | BYL719 |
| Sponsor | NOVARTIS AG (NVS) https://sec-api.dev/companies/nvs/catalysts |
| Indications | [Advanced HER2+Breast Cancer](https://sec-api.dev/indications/advanced-her2-breast-cancer), [PIK3CA-related Overgrowth Spectrum (PROS)](https://sec-api.dev/indications/pik3ca-related-overgrowth-spectrum-pros), [Lymphatic Malformations](https://sec-api.dev/indications/lymphatic-malformations), [Advanced Breast Cancer](https://sec-api.dev/indications/advanced-breast-cancer), [Breast Cancer](https://sec-api.dev/indications/breast-cancer), [Breast Neoplasms](https://sec-api.dev/indications/breast-neoplasms) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### May 24, 2019: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212526 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20190524, review_priority PRIORITY; sponsor_name NOVARTIS; product PIQRAY (ALPELISIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212526%22

### April 5, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215039 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20220405, review_priority PRIORITY; sponsor_name NOVARTIS; product VIJOICE (ALPELISIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215039%22

### November 22, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212526 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20221122, review_priority STANDARD; sponsor_name NOVARTIS; product PIQRAY (ALPELISIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212526%22

### January 18, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212526 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20240118, review_priority PRIORITY; sponsor_name NOVARTIS; product PIQRAY (ALPELISIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212526%22

### April 24, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218466 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20240424, review_priority STANDARD; sponsor_name NOVARTIS; product VIJOICE (ALPELISIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218466%22

### April 24, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215039 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20240424, review_priority STANDARD; sponsor_name NOVARTIS; product VIJOICE (ALPELISIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215039%22

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04544189 (Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT04544189

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05038735 (Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05038735

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05038735 (Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05038735

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04544189 (Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT04544189

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Advanced HER2+Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04208178 (Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT04208178

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Advanced Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04524000 (Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT04524000

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Advanced HER2+Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04208178 (Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT04208178

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Advanced Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04524000 (Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT04524000

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: PIK3CA-related Overgrowth Spectrum (PROS).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04980833 (Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT04980833

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: PIK3CA-related Overgrowth Spectrum (PROS).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04980833 (Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT04980833

### May to Aug 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Lymphatic Malformations.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05948943 (Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05948943

### May 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Lymphatic Malformations.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05948943 (Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05948943

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: PIK3CA-related Overgrowth Spectrum (PROS).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06997588 (EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06997588

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: PIK3CA-related Overgrowth Spectrum (PROS).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06997588 (EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06997588

## Same indication

- [VERZENIO (abemaciclib)](https://sec-api.dev/pdufa/abemaciclib) (LLY)
- [Arm a: gedatolisib + palbociclib + fulvestrant](https://sec-api.dev/pdufa/arm-a-gedatolisib-palbociclib-fulvestrant) (CELC)
- [Etcamah (camizestrant)](https://sec-api.dev/pdufa/camizestrant) (AZN)
- [Truqap (capivasertib)](https://sec-api.dev/pdufa/capivasertib) (AZN)
- [Dato-dxd](https://sec-api.dev/pdufa/dato-dxd) (AZN)
- [Imfinzi® (durvalumab)](https://sec-api.dev/pdufa/durvalumab) (AZN)
- [Revtorpyk (gedatolisib)](https://sec-api.dev/pdufa/gedatolisib) (CELC)
- [Inluriyo™ (imlunestrant)](https://sec-api.dev/pdufa/imlunestrant) (LLY)
- [Iza-bren](https://sec-api.dev/pdufa/iza-bren) (BMY)
- [Palazestrant](https://sec-api.dev/pdufa/palazestrant) (OLMA)
- [IBRANCE® (palbociclib)](https://sec-api.dev/pdufa/palbociclib) (PFE)
- [Pcs6422 and capecitabine](https://sec-api.dev/pdufa/pcs6422-and-capecitabine) (PCSA)
- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [PF-07220060](https://sec-api.dev/pdufa/pf-07220060) (PFE)
- [PF-07248144](https://sec-api.dev/pdufa/pf-07248144) (PFE)
- [Sv-br-1-gm](https://sec-api.dev/pdufa/sv-br-1-gm) (BCTX)
- [Tukysa (tucatinib)](https://sec-api.dev/pdufa/tucatinib) (PFE)
- [(z)-endoxifen](https://sec-api.dev/pdufa/z-endoxifen) (ATOS)

Calendar months: [January 2027](https://sec-api.dev/fda-calendar/2027-01), [February 2027](https://sec-api.dev/fda-calendar/2027-02), [June 2027](https://sec-api.dev/fda-calendar/2027-06), [May 2028](https://sec-api.dev/fda-calendar/2028-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/alpelisib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Piqray (alpelisib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/alpelisib

```bibtex
@misc{secapidev_pdufa_alpelisib_20261116,
  title        = {Piqray (alpelisib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/alpelisib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_alpelisib_20261116","title":"Piqray (alpelisib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/alpelisib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
